At present, a large number of studies have demonstrated that c-Met generally exerts a crucial function of promoting tumor cells proliferation and differentiation in digestive system tumors. c-Met also mediates tumor progression and drug resistance by signaling interactions with other oncogenic molecules and then activating downstream pathways. Therefore, c-Met is a promising target for the treatment of digestive system tumors. Many anti-tumor therapies targeting c-Met (tyrosine kinase inhibitors, monoclonal antibodies, and adoptive immunotherapy) have been developed in treating digestive system tumors. Some drugs have been successfully applied to clinic, but most of them are defective due to their efficacy and complications. In order to promote the clinical application of targeting c-Met drugs in digestive system tumors, it is necessary to further explore the mechanism of c-Met action in digestive system tumors and optimize the anti-tumor treatment of targeting c-Met drugs. Through reading a large number of literatures, the author systematically reviewed the biological functions and molecular mechanisms of c-Met associated with tumor and summarized the current status of targeting c-Met in the treatment of digestive system tumors so as to provide new ideas for the treatment of digestive system tumors.
Background Studies have found that c-Met plays a critical role in the progression of solid tumors. This study aimed to investigate the expression of c-Met in gastric cancer (GC) and its correlation with preoperative serum tumor markers and prognosis, in order to provide a more theoretical basis for targeting c-Met in the treatment of GC. Methods Ninety-seven patients who underwent curative gastrectomy in our hospital from December 2013 to September 2015 were included in this study. The tissue microarray was constructed by paraffin-embedded tumor tissue of enrolled patients, including 97 GC points and 83 paracancerous points. Then, it was used for c-Met immunohistochemical staining, followed by an immunological H-score. The clinical baseline data and 5-year survival of patients with low and high c-Met expression were compared. Besides, the correlation between the expression of c-Met in tumor tissues and preoperative serum tumor markers was investigated. Finally, multivariate Cox regression analysis was used to explore the survival risk factors of patients. Results c-Met has a high expression rate in GC tissues 64.95% (63/97). The expression of c-Met was significantly different in different clinicopathological stages (p < 0.05); the high expression group also had a higher M stage and clinicopathological stage of GC. The correlation test between the c-Met H-score and CA125 was statistically significant (p = 0.004), indicating a positive correlation. Furthermore, high c-Met expression correlated with poor overall survival (OS) for 5 years (p = 0.005). It was also found that the high expression of c-Met in stage I–II patients was correlative with poor OS for 5 years (p = 0.026), while stage III–IV patients had no statistical significance (p > 0.05). Multivariate Cox regression analysis showed that c-Met might be an independent risk factor for survival 5 years after surgery. Conclusion This study found that the high expression of c-Met in GC tissues was associated with poor 5-year OS in GC patients and was an independent risk factor for 5-year survival after curative gastrectomy. The expression of c-Met in GC tissues was also positively correlated with preoperative serum CA125.
No abstract
Background: Studies have found that c-Met plays a critical role in the progression of solid tumors. This study aimed to investigate the expression of c-Met in gastric cancer (GC) and its correlation with blood tumor markers and prognosis. In order to provide a new idea and method for targeting c-Met in the treatment of GC.Methods: Ninety-seven patients who underwent GC surgery in our hospital from December 2013 to September 2015 were included in this study. The tissue microchip was constructed by paraffin cutting, including 97 GC points and 83 para-cancer points. Then, it was used for c-Met immunohistochemical staining, followed by immunological H-score. The expression of c-Met was compared with clinicopathological features, blood tumor markers (AFP, CEA, CA199, CA153, CA125, CA50) and 5-year survival. Descriptive statistics, Pearson correlation test, Kaplan-Meyer survival curve and COX regression were used for statistical analysis.Results: The high expression rate of c-Met was 64.95% (63/97) in GC tissues, and 28.92% (24/83) in para-cancer tissues. There were prominent statistical differences in the M-stage and clinicopathological stage between the low and high expression groups (P<0.05), the c-Met high expression group also had a higher M-stage and clinicopathological stage of GC. The correlation test between the c-Met H-score and CA125 was statistically significant (P=0.004), indicating a positive correlation. High c-Met expression correlated with poor overall survival (OS) for 5 years (HR=2.103, P=0.005). After the clinicopathological classification of patients, it was found that the high expression of c-Met in stage Ⅰ-Ⅱ patients was correlative with poor OS for 5 years (HR=2.486, P=0.026), while stage Ⅲ-Ⅳ patients had no statistical significance (P>0.05). Univariate and multivariate COX regression analysis showed that age, clinicopathological stage, c-Met high expression and preoperative serum AFP might be independent risk factors for survival 5 years after surgery.Conclusion: This study found that the high expression of c-Met in GC was associated with poor 5-year OS in GC patients and was an independent risk factor for 5-year survival after GC surgery. The expression of c-Met in GC was positively correlated with preoperative serum CA125.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.